Rationale, opportunities, and reality of biosimilar medications

New England Journal of Medicine

24 May 2018 - Biosimilars work like established therapeutic agents but have some dissimilarities based on differences in production. 

These agents should be less expensive than, but as effective as, their patented relatives, but several barriers keep the advantage from being realised.

Read New England Journal of Medicine article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Biosimilar